Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Prilenia Appoints Frederick (Rick) Munschauer As Chief Medical Officer
PRIVATESep 08, 2026•about 3 hours ago
Position
Chief Medical Officer
Company
Prilenia
Frederick (Rick) Munschauer
BostonBiotechnologyHealth CareTherapeutics
Description
Prilenia Therapeutics B.V. has announced the appointment of Frederick (Rick) E. Munschauer III, MD, MSc, FAAN, as its new Chief Medical Officer
Company Information
Company
Prilenia
Location
Boston, Massachusetts, United States
About
Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders.
Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children.
Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial.
The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018.
Don't miss Prilenia's next move
Get an email the moment Prilenia changes its leadership, hires an exec, or expands, usually minutes after it happens.
BostonBiotechnologyHealth CareTherapeutics